International Journal of Medical and Pharmaceutical Research
2023, Volume-4, Issue-4 doi: 10.5281/zenodo.8179305
Original Article
A Prospective Study for Comparison of Dosimetric Analysis, Radiation Induced Toxicities and Response in Flattening Filter Versus Flattening Filter Free Beam in Oral Cavity Cancers
 ,
 ,
 ,
 ,
 ,
Published
July 24, 2023
Abstract

Aim: This study aimed to compare the response, dosimetric parameters and toxicities of IMRT with Flattening Filter(FF) photon beam and Flattening Filter Free(FFF)photon beam in Oral Cavity cancers.

 

Material and Methods-This study was conducted as prospective observational study on total of 60 cases of oral cavity cancerat our institute during study period of 2 years. All 60 participants were randomly assigned into either of the two treatment group IMRT-FF and IMRT-FFF.Patients were followed and assessment of dosimetric parameters, response and toxicities grading was done.

 

Results- Two groups were comparable with respect to baseline variables and tumor characteristics and treatment (p>0.05).  Mean number of fractions, as well as dose to brainstem, spinal cord and parotid were significantly higher in FF group as compared to FFF group (p<0.05). The response rate following radiation was found to be significantly better in FFF group as compared to FF group (p<0.05). Skin toxicities were significantly higher in FFF group at 3 months (p<0.05) whereas parotid as well as oral cavity were significantly higher in FF group at 3 and 6 months (p<0.05).

 

Conclusions-Intensity Modulated Radiation Therapy (IMRT) is common modality used for management of oral cavity cancer. FF photon beam and FFF photon beam, both modalities were compared in this study and we found that removal of flattening filter helps in equivalent delivery of dose of radiation to target tissue, with reduced scattering and leakage of radiation dose to adjacent normal tissues thereby reducing the risk of toxicities of organ at risks.

Recommended Articles
Loading Image...
Volume-4, Issue-4
Citations
2271 Views
352 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved